Cytokine mRNA-based therapy alleviates dendritic cell and T cell paucity to eliminate aggressive pancreatic cancer in preclinical mouse models
Key Points
Cytokine mRNA therapy effectively alleviates dendritic cell and T cell scarcity, targeting pancreatic cancer.
Improvements in immune response can enhance cancer elimination rates in aggressive pancreatic cancer.
Assessment of therapy in preclinical mouse models highlights its potential efficacy against pancreatic cancer.
Further investigations in human models could validate the therapeutic approach and its broad applicability.
Abstract
This work was supported by Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT), Japan Agency for Medical Research and Development (AMED), and the Princess Takamatsu Cancer Research Fund.
Cytokine mRNA-based therapy alleviates dendritic cell and T cell paucity to eliminate aggressive pancreatic cancer in preclinical mouse models | Synapse
Also Consider
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: